


Venue

Harnack-Haus of the Max-Planck Society

Ihnestraße 16-20, 14195 Berlin

26.04.23, 12:00 – 19:00

27.04.23, 9:00 – 16:15



Addresses of speakers, chairpersons and moderators

Charité – Universitätsmedizin Berlin

Dr. Francis Baumgartner
Prof. Dr. Lars Bullinger
PD Dr. Antonia Busse
Prof. Dr. Björn Chapuy
Prof. Dr. Frederik Damm
PD Dr. Martin Janz
Prof. Dr. Ulrich Keller
Prof. Dr. Jan Krönke
Dr. Corinna Leng
Prof. Dr. Stephan Mathas
Dr. Rebecca Wurm-Kuczera

Berliner Institut für Gesundheitsforschung in der Charité

Prof. Dr. Il-Kang Na

Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft, Berlin

Prof. Dr. Kathrin De la Rosa
Dr. Simon Haas
PD Dr. Uta Höpken
Dr. Philipp Mertins
Prof. Dr. Nikolaus Rajewsky

Hôpital Saint-Louis, France

Prof. Dr. Catherine Thieblemont

Institute of Oncology Research (IOR), Switzerland

Prof. Dr. Davide Rossi

Kepler Universitätsklinikum Linz, Austria

Prof. Dr. Clemens Schmitt

Klinikum der Ludwig-Maximilians-Universität München

Prof. Dr. Marion Subklewe

Prof. Dr. Oliver Weigert

Klinikum Stuttgart

Prof. Dr. Gerald Illerhaus

Medical University of Vienna, Austria

Prof. Dr. Philipp Staber

Technische Universität München

Prof. Dr. Roland Rad

Universitätsklinikum Essen

Prof. Dr. Christian Reinhardt

Universitätsklinikum Freiburg

PD Dr. Florian Scherer

Universitätsklinikum Halle (Saale)

Prof. Dr. Mascha Binder

Universitätsklinikum Heidelberg

Prof. Dr. Sascha Dietrich

Universitätsklinikum Frankfurt a. M.

Prof. Dr. Thomas Oellerich

Universitätsklinikum Köln

Prof. Dr. Barbara Eichhorst

Universitätsklinikum Schleswig-Holstein

Prof. Dr. Christiane Pott

Universitätsklinikum Ulm

Prof. Dr. Reiner Siebert

Prof. Dr. Stephan Stilgenbauer

University Hospital Southampton, UK

Prof. Dr. Andrew Davies

Scientific Management

Prof. Dr. med. Ulrich Keller

Prof. Dr. med. Björn Chapuy

Registration

We kindly ask for registration by

registration form via email to:

Jasmin.Radenkovic@charite.de

Subject line starting with: „REGISTRATION“

Application to be certified as educational event has been submitted to Ärztekammer Berlin.

Under the auspices of:

dkfz.
German Cancer Consortium
Partner site Berlin

GLA
German Lymphoma Alliance

Kompetenznetz Maligne Lymphome

With the kind support of:

abbvie

AstraZeneca

BeiGene

Bristol Myers Squibb™

Incyte

Janssen Oncology
PHARMACEUTICAL COMPANIES OF *jnj.com*

Kite
A GILEAD Company


Lilly

MSD

NOVARTIS

Roche

Takeda



2023 Conference

Berlin Conference on Lymphoma (B-CoL)

Cancer dynamics in time and space

Berlin, April 26 - 27 2023

Harnack-Haus of the Max-Planck Society

Layout: CV Zentrale Medienleistungen Charité. Fotos: commons.wikimedia.org. Webke Fetz GB/UK Charité CC0/1/2023

PROGRAM



Dear colleagues and friends,

It is with great pleasure that we invite you to the 2023 Berlin Conference on Lymphoma (B-CoL). After a longer SARS-CoV2 pandemic-triggered break, we now reinvigorate this two-day event that brings together key opinion leaders in the clinical management of lymphoma patients and translational lymphoma researchers.

The scientific topic of the 2023 Berlin Conference on Lymphoma is Cancer dynamics in time and space. The B-CoL will take place at the Harnack-Haus of the Max-Planck Society on April 26 and April 27. Notably, we are pleased to announce Prof. Nikolaus Rajewsky as keynote speaker. We are looking forward to meeting you for this certainly vibrant and stimulating meeting.

Ulrich Keller und Björn Chapuy

Day 1 (April 26 from 12:00 - 19:00)

12:00 Registration/Welcome reception

12:45 **U. Keller** – Welcome

13:00 Clinic Session I – CLL

Moderators: L. Bullinger/F. Damm

B. Eichhorst – Treatment algorithms of CLL - quo vadis?
D. Rossi – MRD triggered therapy in CLL
S. Stilgenbauer – High-risk CLL and Richter - lessons from genomics

14:30 1st Coffee break

15:00 Clinic Session II – Aggressive lymphoma

Moderators: B. Chapuy/A. Busse

A. Davies – 1L treatment of DLBCL: R-CHOP and beyond
C. Thieblemont – Novel developments for r/rDLBCL
F. Scherer – Liquid biopsy guided therapy – are we there?
R. Wurm-Kuczera – Patient-reported outcome analysis (short talk)
G. Illerhaus – Treatment paradigms for CNS lymphoma/CNS prophylaxis

17:00 2nd Coffee break

17:30 Clinic Session III – Indolent lymphoma

Moderators: M. Janz/C. Leng

C. Pott – Therapy algorithm MCL and the role of MRD-triggered therapy
M. Subklewe – To CART or BITE relapsed/refractory indolent/aggressive lymphoma?
O. Weigert – Risk prediction and patient stratification in follicular lymphoma

18:55 **B. Chapuy** – Closing remarks Day 1

Day 2 (April 27 from 9:00 - 16:15)

9:00 **U. Keller** – Welcome

9:05 Translational Session I

Moderators: U. Keller/P. Mertins

R. Rad – Exploiting new targets using functional genomics
F. Baumgartner – Single cell sequencing for genome-wide cancer gene discovery screening (short talk)
B. Chapuy – Genomic signatures in DLBCL/precision medicine - where are we?

10:00 1st Coffee break

10:20 Translational Session II

Moderators: U. Keller/P. Mertins

M. Binder – Germline variants in lymphoid malignancies
R. Siebert – Epigenetic signatures
T. Oellerich – Proteogenomic strategies on lymphoma

11:15 Keynote Lecture – Prof. Dr. Nikolaus Rajewksy

12:00 Lunch break

13:00 Translational Session III – Lymphoma as an organ, Role of the TME: Moderators: B. Chapuy/S. Mathas

K. De la Rosa – B cells at the crossroad of diversification and malignant transformation
C. Reinhardt – Lessons from mouse models
S. Dietrich – Intratumoral heterogeneity/CODEX
S. Haas – Dissecting tumor heterogeneity and reverse translation

14:30 2nd Coffee break

15:00 Translational Session IV – Development of new treatments: Moderators: I.-K. Na/J. Krönke

C. Schmitt – Harnessing senescence as a therapeutic target in lymphoma
U. Höpken – Novel cellular therapies
A. Busse – Adoptive T cell therapies: phase I Charité studies (short talk)
P. Staber – Can we EXALT response by ex vivo drug testing?

16:00 **B. Chapuy** – Closing remarks / Farewell